Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
Jiahui Liu, Wenqiang Yan, Huishou Fan...
https://pubmed.ncbi.nlm.nih.gov/37680953/Actively Recruiting
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2026-02-12
2300
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a large-scale, long-term observational study to better understand major blood diseases in China. This study aims to analyze the incidence, risk factors, treatments, prognosis, and medical costs related to various hematological conditions such as acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, and others. The study includes patients who have received bone marrow transplantation and fills a gap due to limited prior cohort data in China. The study collects information from patients diagnosed with these blood diseases in participating hospitals starting from January 1, 2020. It gathers data prospectively and retrospectively from medical records, including basic patient information, diagnosis, treatment details, prognosis, and medical expenses. The NICHE registry includes historical data from 2000 and continues to collect prospective follow-up data in phases, broadening its reach. Participants data will be monitored over at least five years to assess the incidence and distribution of blood diseases, evaluate treatments, and analyze healthcare costs. The study does not involve experimental treatments but focuses on collecting and analyzing real-world clinical information. Researchers will use this data to better understand disease patterns and outcomes, with follow-ups planned to gather ongoing prognosis details and economic evaluations.
CONDITIONS
National Longitudinal Cohort of Hematological Diseases
Z
Zhen Song, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed over time to collect long-term data on their hematological diseases.
Periodic visits depending on clinical follow-up
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Jiahui Liu, Wenqiang Yan, Huishou Fan...
https://pubmed.ncbi.nlm.nih.gov/37680953/Jian Cui, Rui Lv, Tengteng Yu...
https://pubmed.ncbi.nlm.nih.gov/37534514/Ni Lu, Li Liu, Yigeng Cao...
https://pubmed.ncbi.nlm.nih.gov/40353947/Jian Cui, Tengteng Yu, Rui Lv...
https://pubmed.ncbi.nlm.nih.gov/38249329/Wenqiang Yan, Lihui Shi, Jingyu Xu...
https://pubmed.ncbi.nlm.nih.gov/39095502/Hongye Gao, Jiali Wang, Xinhui Zheng...
https://pubmed.ncbi.nlm.nih.gov/38505288/Huishou Fan, Bing Wang, Lihui Shi...
https://pubmed.ncbi.nlm.nih.gov/38170583/Wenqiang Yan, Jingyu Xu, Huishou Fan...
https://pubmed.ncbi.nlm.nih.gov/37846845/Huishou Fan, Weida Wang, Ya Zhang...
https://pubmed.ncbi.nlm.nih.gov/36647781/Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor